Stemline Therapeutics Inc Revenue Growth Rates (STML), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Stemline Therapeutics Inc  (STML)
 

STML's Revenue Growth by Quarter and Year

Stemline Therapeutics Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

STML Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 8.87
FY 8.87

STMLs Annual Revenue
Stemline Therapeutics Inc's Revenue in the fiscal year 2019 $ 43.22 millions
Stemline Therapeutics Inc's Revenue in the fiscal year 2018 $ 0.50 millions
Stemline Therapeutics Inc's Revenue in the fiscal year 2017 $ 0.90 millions
Stemline Therapeutics Inc's Revenue in the fiscal year 2016 $ 1.04 millions
Stemline Therapeutics Inc's Revenue in the fiscal year 2015 $ 0.65 millions




STML Revenue first quarter 2020 Y/Y Growth Comment
Stemline Therapeutics Inc reported Revenue surge of 75.7% year on year in the first quarter 2020, to $ 8.87 millions, this is lower than Stemline Therapeutics Inc's recent average Revenue surge of 470.41%.

Looking into first quarter 2020 results within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Revenue growth. While Stemline Therapeutics Inc' s Revenue jump of 75.7% ranks overall at the positon no. 289 in the first quarter 2020.


STML Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - - - -
3rd Quarter September - - - 0 %
2nd Quarter June - 2502 % 66.67 % 25 %
1st Quarter March 75.7 % - - 42.86 %
FY   - 8544 % -44.44 % -

Financial Statements
Stemline Therapeutics Inc's first quarter 2020 Revenue $ 8.87 millions STML's Income Statement
Stemline Therapeutics Inc's first quarter 2019 Revenue $ 5.05 millions Quarterly STML's Income Statement


STML Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - -11.25 % - -
3rd Quarter September - 2.46 % - 0 %
2nd Quarter June - 157.62 % - 0 %
1st Quarter March -25 % - - 0 %
FY (Year on Year)   - 8544 % -44.44 % -


Back to STML Growth rate Comparisons >> Back to STML Growth rate Comparisons >>


Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #89
Overall #289

Revenue Y/Y Growth Statistics
High Average Low
5796.71 % 470.41 % -100 %
(Dec 31 2019)   (Sep 30 2018)
Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #89
Overall #289
Revenue Y/Y Growth Statistics
High Average Low
5796.71 % 470.41 % -100 %
(Dec 31 2019)   (Sep 30 2018)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Stemline Therapeutics Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2416.71 % 114.64 % -100 %
(Mar 31 2019)  


STML's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Stemline Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -25% to $ 8.87 millions, from $ 11.83 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Revenue quarter on quarter growth. While Stemline Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 3355.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #186
Healthcare Sector #469
Overall #3355
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #186
Healthcare Sector #469
Overall #3355
Revenue Q/Q Growth Statistics
High Average Low
2416.71 % 114.64 % -100 %
(Mar 31 2019)  


STML's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Stemline Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -25% to $ 8.87 millions, from $ 11.83 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Revenue quarter on quarter growth. While Stemline Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 3355.


Stemline Therapeutics Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)
Cumulative Revenue 12 Months Ending $ 47.04 $ 43.22 $ 31.59 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 8.85 % 36.81 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 438 # 461 # 463 # 0 # 0


Cumulative Revenue growth Comment
Stemline Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 75.7% year on year, to $ 47 millions if the fiscal year would have ended in Mar 31 2020.
Stemline Therapeutics Inc's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Dec 31 2019. And, Stemline Therapeutics Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Dec 31 2019 rise was beneth at 8.85 % from $43.22 millions achieved in the period from Dec 31 2019 to Mar 31 2019.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at69.82%.

Stemline Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 56
Sector # 114
S&P 500 # 438
Cumulative Revenue growth Comment
Stemline Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 75.7% year on year, to $ 47 millions if the fiscal year would have ended in Mar 31 2020.
Stemline Therapeutics Inc's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Dec 31 2019. And, Stemline Therapeutics Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Dec 31 2019 rise was beneth at 8.85 % from $43.22 millions achieved in the period from Dec 31 2019 to Mar 31 2019.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at69.82%.
The momentum is even more impressive from twelve months ended Dec 31 2019 exhibited at 8.85 % increase from $43.22 millions in the period from Dec 31 2019 to Mar 31 2019.

Stemline Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 56
Sector # 114
S&P 500 # 438




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
STML's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2020
Cogent Biosciences Inc 130.30%$ 130.298 millions
Avita Medical Inc 126.73%$ 126.725 millions
Arbutus Biopharma Corp119.59%$ 119.588 millions
Q32 Bio Inc 117.78%$ 117.778 millions
Momenta Pharmaceuticals inc 116.12%$ 116.120 millions
Exact Sciences Corporation114.65%$ 114.647 millions
Sintx Technologies Inc 113.40%$ 113.402 millions
Amarin Corp Plcuk111.51%$ 111.514 millions
Biolife Solutions Inc 110.78%$ 110.780 millions
Shockwave Medical Inc 109.07%$ 109.066 millions
Biotricity Inc 103.73%$ 103.727 millions
Castle Biosciences Inc 99.82%$ 99.816 millions
Ultragenyx Pharmaceutical Inc 99.81%$ 99.807 millions
Fortress Biotech Inc 99.44%$ 99.444 millions
Geovax Labs Inc 96.57%$ 96.572 millions
Biodelivery Sciences International Inc 93.63%$ 93.626 millions
Skinvisible Inc 91.85%$ 91.849 millions
Edgemode Inc 91.67%$ 91.667 millions
Celldex Therapeutics inc 91.44%$ 91.439 millions
Flexion Therapeutics Inc 90.52%$ 90.524 millions
Dynavax Technologies Corporation89.14%$ 89.139 millions
Aerie Pharmaceuticals Inc 87.44%$ 87.440 millions
Misonix Inc 87.33%$ 87.332 millions
Nexgel Inc 86.05%$ 86.047 millions
Athenex Inc 85.46%$ 85.463 millions
Tvardi Therapeutics Inc 84.69%$ 84.687 millions
Guardant Health Inc 84.18%$ 84.177 millions
Bristol myers Squibb Company82.11%$ 82.111 millions
Ontrak Inc 81.15%$ 81.148 millions
Genmark Diagnostics Inc 79.92%$ 79.919 millions


About Stemline Therapeutics Inc Revenue Growth Rates (STML), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.